IS5812A - 2-setin-1-píperidýl bensimídasól efnasambönd sem ORL1-viðtaka gerandefni - Google Patents

2-setin-1-píperidýl bensimídasól efnasambönd sem ORL1-viðtaka gerandefni

Info

Publication number
IS5812A
IS5812A IS5812A IS5812A IS5812A IS 5812 A IS5812 A IS 5812A IS 5812 A IS5812 A IS 5812A IS 5812 A IS5812 A IS 5812A IS 5812 A IS5812 A IS 5812A
Authority
IS
Iceland
Prior art keywords
piperidyl
substituted
receptor agonists
benzimidazole compounds
orl1 receptor
Prior art date
Application number
IS5812A
Other languages
English (en)
Inventor
Ito Fumitaka
Noguchi Hirohide
Kondo Hiroshi
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS5812A publication Critical patent/IS5812A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5812A 1998-08-06 2001-01-16 2-setin-1-píperidýl bensimídasól efnasambönd sem ORL1-viðtaka gerandefni IS5812A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IBPCT/IB98/01206 1998-08-06
PCT/IB1999/001239 WO2000008013A2 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists

Publications (1)

Publication Number Publication Date
IS5812A true IS5812A (is) 2001-01-16

Family

ID=11004738

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5812A IS5812A (is) 1998-08-06 2001-01-16 2-setin-1-píperidýl bensimídasól efnasambönd sem ORL1-viðtaka gerandefni

Country Status (44)

Country Link
US (1) US6172067B1 (is)
EP (1) EP1102762B1 (is)
JP (1) JP3367945B2 (is)
CN (1) CN1317968A (is)
AP (1) AP2001002063A0 (is)
AR (1) AR018686A1 (is)
AT (1) ATE227716T1 (is)
AU (1) AU749166B2 (is)
BG (1) BG105301A (is)
BR (1) BR9912778A (is)
CA (1) CA2339621C (is)
CZ (1) CZ2001397A3 (is)
DE (1) DE69903953T2 (is)
DK (1) DK1102762T3 (is)
EA (1) EA200100104A1 (is)
EE (1) EE200100075A (is)
ES (1) ES2185357T3 (is)
GE (1) GEP20033000B (is)
GT (1) GT199900125A (is)
HK (1) HK1040188A1 (is)
HN (1) HN1999000105A (is)
HR (1) HRP20010089B1 (is)
HU (1) HUP0103567A3 (is)
ID (1) ID27212A (is)
IL (1) IL141029A0 (is)
IS (1) IS5812A (is)
MA (1) MA26659A1 (is)
NO (1) NO20010603L (is)
NZ (1) NZ509299A (is)
OA (1) OA11590A (is)
PA (1) PA8477701A1 (is)
PE (1) PE20000868A1 (is)
PL (1) PL346211A1 (is)
PT (1) PT1102762E (is)
SI (1) SI1102762T1 (is)
SK (1) SK1602001A3 (is)
SV (1) SV1999000099A (is)
TN (1) TNSN99142A1 (is)
TR (1) TR200100403T2 (is)
TW (1) TW513424B (is)
UY (1) UY25659A1 (is)
WO (1) WO2000008013A2 (is)
YU (1) YU8201A (is)
ZA (1) ZA200100900B (is)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340681B1 (en) * 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
EP1122257B1 (en) * 2000-01-05 2005-10-12 Pfizer Inc. Benzimidazole compounds as ORL1-receptor agonists
GB2359078A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
AU2403802A (en) * 2000-11-15 2002-05-27 Banyu Pharma Co Ltd Benzimidazole derivatives
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
EP1385518B1 (en) * 2001-04-18 2008-08-06 Euro-Celtique S.A. Benzimidazolone compounds
JP4489354B2 (ja) 2001-04-18 2010-06-23 ユーロ−セルティーク エス．エイ． スピロインデンおよびスピロインダン化合物類
RU2268883C2 (ru) 2001-04-18 2006-01-27 Эро-Селтик, С.А. Аналоги ноницептина и фармацевтическая композиция на их основе
IL158484A0 (en) 2001-04-18 2004-05-12 Euro Celtique Sa Nociceptin analogs
KR100628292B1 (ko) 2001-04-18 2006-09-27 유로-셀티크 소시에떼 아노뉨 스파이로파이라졸 화합물
JP2005502619A (ja) * 2001-07-02 2005-01-27 オメロス コーポレイション オピオイドレセプター様レセプター１アゴニストと交替でオピオイドレセプターアゴニストを投与することを含む、痛覚脱失を生成するための方法
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
AU2002360561A1 (en) * 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
JP4056977B2 (ja) 2002-03-29 2008-03-05 田辺三菱製薬株式会社 睡眠障害治療薬
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10252665A1 (de) 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
GB0315203D0 (en) * 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
AR045939A1 (es) 2003-09-25 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US20050228023A1 (en) * 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
US20080021069A1 (en) * 2004-10-08 2008-01-24 Takeda Pharmaceutical Company Limited Receptor Function Regulating Agent
EP1838306B1 (en) 2005-01-11 2010-11-17 NeuroSearch A/S Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
JP2009541454A (ja) * 2006-07-03 2009-11-26 ノイロサーチ アクティーゼルスカブ モノアミン再摂取阻害剤及びカリウムチャネル活性剤の併用
EP2397477B1 (en) * 2007-01-16 2014-03-05 Purdue Pharma LP Heterocyclic-substituted piperidine compounds and the uses thereof
MY150602A (en) * 2007-08-31 2014-01-30 Purdue Pharma Lp Subtituted-quinoxaline-type piperidine compounds and the uses thereof
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
KR101333660B1 (ko) 2008-07-21 2013-11-27 시오노기세이야쿠가부시키가이샤 치환-퀴녹살린-형 가교-피페리딘 화합물 및 그의 용도
SG10201505997TA (en) 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
MX346043B (es) 2012-01-06 2017-03-03 Novus Int Inc Tensioactivos basados en sulfoxido.
US9284294B2 (en) 2012-02-09 2016-03-15 Novus International, Inc. Functionalized polymer compositions
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
PL2871973T3 (pl) 2012-07-12 2019-02-28 Novus International Inc. Kompozycje matrycy i warstwy do ochrony środków bioaktywnych
US9085561B2 (en) * 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
WO2014102594A2 (en) * 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014153529A1 (en) 2013-03-22 2014-09-25 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
CA2943220C (en) * 2014-03-20 2024-01-16 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
HK1255204A1 (zh) 2015-11-12 2019-08-09 Novus International Inc. 含硫化合物溶剂
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318900A (en) * 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
JPS5297978A (en) * 1976-06-02 1977-08-17 Yoshitomi Pharmaceut Ind Ltd Preparation of alicyclic derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
CA2229202C (en) 1995-08-15 2008-05-20 Universite Libre De Bruxells Methods for identifying antagonist or agonist to human opioid receptor-like 1 "orl1"
US5866346A (en) 1995-09-27 1999-02-02 Indiana Unversity Foundation Methods of using dynorphins as ligands for XOR1 receptor
US6180649B1 (en) * 1996-04-19 2001-01-30 Nerosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
EP0813065A3 (en) 1996-06-13 1998-07-22 F. Hoffmann-La Roche Ag Modulation of LC132 (opioid-like) receptor function
EP0829481A1 (en) * 1996-09-16 1998-03-18 Pfizer Inc. Morphinan hydroxamic acid compounds
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
ES2226129T3 (es) 1997-05-30 2005-03-16 Banyu Pharmaceutical Co., Ltd. Derivados de 2-0x0imidazol.
WO1999003880A1 (en) 1997-07-15 1999-01-28 Novo Nordisk A/S Nociceptin analogues
US5929035A (en) 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1

Also Published As

Publication number Publication date
SV1999000099A (es) 2000-09-05
OA11590A (en) 2004-08-18
TR200100403T2 (tr) 2001-07-23
ID27212A (id) 2001-03-08
AR018686A1 (es) 2001-11-28
JP2002522431A (ja) 2002-07-23
DE69903953T2 (de) 2003-03-27
DK1102762T3 (da) 2002-12-16
ES2185357T3 (es) 2003-04-16
US6172067B1 (en) 2001-01-09
IL141029A0 (en) 2002-02-10
AP2001002063A0 (en) 2001-03-31
HUP0103567A3 (en) 2003-01-28
NO20010603D0 (no) 2001-02-05
WO2000008013A2 (en) 2000-02-17
TNSN99142A1 (fr) 2005-11-10
PE20000868A1 (es) 2000-08-31
PA8477701A1 (es) 2000-09-29
GT199900125A (es) 2001-01-27
EP1102762B1 (en) 2002-11-13
HRP20010089B1 (en) 2003-04-30
DE69903953D1 (de) 2002-12-19
HN1999000105A (es) 2000-11-11
HK1040188A1 (zh) 2002-05-31
CA2339621C (en) 2005-04-05
AU4385999A (en) 2000-02-28
CZ2001397A3 (cs) 2002-05-15
AU749166B2 (en) 2002-06-20
BG105301A (en) 2001-12-29
NZ509299A (en) 2003-05-30
ZA200100900B (en) 2002-08-28
PL346211A1 (en) 2002-01-28
ATE227716T1 (de) 2002-11-15
EE200100075A (et) 2002-06-17
HUP0103567A2 (hu) 2002-02-28
JP3367945B2 (ja) 2003-01-20
MA26659A1 (fr) 2004-12-20
SK1602001A3 (en) 2002-09-10
CA2339621A1 (en) 2000-02-17
SI1102762T1 (en) 2003-04-30
HRP20010089A2 (en) 2002-02-28
PT1102762E (pt) 2003-02-28
YU8201A (sh) 2003-07-07
CN1317968A (zh) 2001-10-17
UY25659A1 (es) 2000-02-23
EP1102762A2 (en) 2001-05-30
WO2000008013A3 (en) 2000-03-23
BR9912778A (pt) 2001-09-25
EA200100104A1 (ru) 2001-08-27
TW513424B (en) 2002-12-11
NO20010603L (no) 2001-04-05
GEP20033000B (en) 2003-06-25

Similar Documents

Publication Publication Date Title
IS5812A (is) 2-setin-1-píperidýl bensimídasól efnasambönd sem ORL1-viðtaka gerandefni
NO20013444L (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
PT1049689E (pt) Compostos de 4-(2-ceto-1-benzimidazolinil)piperidina como agonistas do receptor orl1
PT1189916E (pt) N-pirazole agonistas do receptor a2a
EE200200355A (et) EP4 retseptori selektiivsed agonistid osteoporoosi raviks
HUP0104390A3 (en) Imidazole derivatives as selective agonists at alpha 2b or 2b/2c adrenergic receptors
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
DK1664036T3 (da) Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
AU2003238597A8 (en) Benzimidazole compounds and their use as estrogen agonists/antagonists
IS5532A (is) 2,3-setin indól efnasambönd sem cox-2 latar
PT1192170E (pt) Agonistas de receptor a2a de propargilfenileter
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
EE200200204A (et) Asendatud bensimidasooli preparaat
DK1146874T3 (da) Vitronectinreceptoragonist
NO20014127D0 (no) 5-HT1F agonister
NO20023380D0 (no) Indolderivater som MCP-1-reseptoragonister
NO20013978D0 (no) Dopamin D1 reseptor agonist forbindelser
NO20006041D0 (no) N-Benzodioksanylmetyl-1-piperidyl-metylamin-forbindelser med affinitet for 5-HT-reseptorer
SI1077935T1 (en) Phenylsulfonamide-phenylethylamines useful as dopamine receptors